July 24, 2019July 24, 2019

Innovation and Alfasigma Ink Pact to Develop and Commercialize Brilacidin for Types of IBD

News

Innovation Pharmaceuticals now has a global licensing agreement with Alfasigma for the development and commercialization of the therapy Brilacidin for treating ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), types of inflammatory bowel disease (IBD). ... Read more

March 23, 2017March 23, 2017

Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix

News

Cellceutix announced additional interim positive findings from its ongoing Phase 2a trial evaluating brilacidin (PMX-30063) as a treatment for two types of inflammatory bowel disease (IBD) – ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). ... Read more